Copy Link Print Information

Troglitazone

(Synonyms: CS-045)
35 Cited Publications
Avis client

Based on 35 publication(s) in Google Scholar

Troglitazone is an orally active PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively. Troglitazone has anticancer activity, prevents and inhibits the development of type 2 diabetes.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.78%
  • CAS No.: 97322-87-7
  • Formule: C24H27NO5S
  • Masse moléculaire:441.54
  • Stockage:
    Powder   -20°C, 3 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • Troglitazone Chemical Structure
    Troglitazone Chemical Structure
  • Experimental Validation Results for Troglitazone
  • Experimental Validation Results for Troglitazone
  • Experimental Validation Results for Troglitazone
  • Experimental Validation Results for Troglitazone
  • Experimental Validation Results for Troglitazone
  • Experimental Validation Results for Troglitazone
  • Experimental Validation Results for Troglitazone
  • Experimental Validation Results for Troglitazone
  • Experimental Validation Results for Troglitazone
CAS No.: 97322-87-7
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Troglitazone:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Protocole
  • Pureté et documentation
  • Références
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Troglitazone

More
Customer Validation & Images
Histological Imaging/StainingCell Proliferation/Viability AssayELISACell Imaging/StainingFlow CytometryWB
  • Flow Cytometry
  • Cell Proliferation/Viability Assay
  • Cell Imaging/Staining
  • Histological Imaging/Staining
  • ELISA
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • WB
  • WB

Voir tous les produits spécifiques à Isoform PPAR

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Troglitazone Chemical Structure
    Troglitazone Chemical Structure
    1/16
  • 1/16

    Troglitazone purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 31;16(1):1217. [Abstract]

    Customer Validation
     BMDM treated with the PPAR-γ agonist Troglitazone (50 μM, 48 h) significantly inhibited 25-HC ability to prevent the induction of “M2-like” BMDM by the TCM.

  • 1/16

    Troglitazone purchased from MedChemExpress. Usage Cited in: Biomater Res. 2025 Nov 7:29:0280. [Abstract]

    Customer Validation
     Dose-dependent toxicity curves of Troglitazone (0, 0.1, 1, 5, 10, 50, 100, 500, and 1,000 μM) showing cell viabilities among P-hep-orgs, NP-hep-spheres, and HepG2-3D 48 h after the treatment.

  • 1/16

    Troglitazone purchased from MedChemExpress. Usage Cited in: Biomater Res. 2025 Nov 7:29:0280. [Abstract]

    Customer Validation
     Compared to controls, significant reduction in CDF fluorescence were observed in P-hep-orgs treated with Troglitazone.

  • 1/16

    Troglitazone purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Jun 18;43(7):114364. [Abstract]

    Customer Validation
     Human skin explants were cultured under indicated conditions in the presence or absence of GW3965 or Troglitazone (100 μM) for 48 h. Representative histological images of skin explants.

  • 1/16

    Troglitazone purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Jun 18;43(7):114364. [Abstract]

    Customer Validation
     Human skin explants were cultured under indicated conditions in the presence or absence of GW3965 or Troglitazone (0, 10, 100 μM) for 48 h. Culture supernatant IL-17A was measured by ELISA.

  • 1/16

    Troglitazone purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005. [Abstract]

    Customer Validation
     HT22 cells were pretreated with the indicated inhibitors and then treated with T/Z, T/S/Z, T/C/Z for 9 h or Glutamate, Erastin (T: 20 ng/ml; Z: 50 μM; S: 20 nM; C: 1 μg/ml; Glutamate: 50 mM; Erastin 10 μM) for 12 h. Cell viability was measured by CellTiterGlo assay. Troglitazone inhibited ferroptosis but not necroptosis.

  • 1/16

    Troglitazone purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005. [Abstract]

    Customer Validation
     HT22 cells were pretreated with the indicated inhibitors (CDDO (Bardoxolone, HY-14909); T0070907 (HY-13202); Troglitazone (HY-50935 ); TPCA-1 (HY-10074); JAKi; STAT3i; AV-412 (HY-10346); and MK2206 (HY-10358)) and then treated with T/Z, T/S/Z, T/C/Z for 9 h or Glutamate, Erastin (T: 20 ng/ml; Z: 50 μM; S: 20 nM; C: 1 μg/ml; Glutamate: 50 mM; Erastin 10 μM) for 12 h. Cell viability was measured by CellTiterGlo assay.

  • 1/16

    Troglitazone purchased from MedChemExpress. Usage Cited in: Yonsei Med J. 2018 Nov;59(9):1096-1106.  [Abstract]

    Customer Validation
     MCN and N2a cells are treated with Control (DMSO), Troglitazone (Tro; 20 µM), or GW9662 (10 µM) for 24 h, followed by detection of PPAR-γ protein level via Western blot assay.

  • 1/16

    Troglitazone purchased from MedChemExpress. Usage Cited in: Breast Cancer Res Treat. 2017 Oct;165(3):517-527. [Abstract]

    Customer Validation
     MDA-MB-231 and Hs578T TNBC ‘‘claudin-1-low’’ cells, and the non-tumorigenic human breast epithelial cell line MCF-10A are treated with 20 μM of Troglitazone(TGZ), RGZ, D2-TGZ, or DMSO (Ctrl) for 24 h and subjected to western blot analysis with claudin-1 (CLDN1) antibody. α-tubulin is used as loading control.

  • Troglitazone